Biotech firm Pacific Edge says it's raised $11.4 million through a placement of shares to institutional and habitual investors.
About 72% of the offer has been taken up, which aimed to raise about $16 million to fund the commercialisation of its Cxbladder product in the United States.
Cxbladder can detect bladder cancer and is non-invasive and cheaper than current tests.
Large investors will get a chance to pick up the shortfall through a book build on Friday.
